Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call at 4:30 pm ET to discuss the results. The company has delivered nearly four million Motiva® devices across 85+ countries since 2010, and offers solutions including the Motiva Flora® tissue expander and Mia Femtech™. Establishment Labs operates two FDA-compliant manufacturing facilities in Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), un'azienda globale di tecnologia medica focalizzata sulla salute delle donne e sull'estetica mammaria, rilascerà i suoi risultati finanziari del Q3 2024 il 7 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ET per discutere i risultati. L'azienda ha consegnato quasi quattro milioni di dispositivi Motiva® in oltre 85 paesi dal 2010 e offre soluzioni che includono l'espansore tissutale Motiva Flora® e Mia Femtech™. Establishment Labs gestisce due strutture di produzione conformi alla FDA in Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), una empresa global de tecnología médica enfocada en la salud de las mujeres y la estética mamaria, publicará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado. La empresa realizará una llamada de conferencia a las 16:30 ET para discutir los resultados. Desde 2010, la compañía ha entregado casi cuatro millones de dispositivos Motiva® en más de 85 países y ofrece soluciones que incluyen el expansor de tejido Motiva Flora® y Mia Femtech™. Establishment Labs opera dos instalaciones de fabricación conformes a la FDA en Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), 여성 건강 및 유방 미용에 중점을 둔 글로벌 의료 기술 회사는 2024년 11월 7일, 시장 마감 후에 2024년 3분기 재무 결과를 발표할 예정입니다. 회사는 결과를 논의하기 위해 동부 표준시 기준 오후 4:30에 컨퍼런스 콜을 주최합니다. 2010년 이후로, 이 회사는 85개국 이상에 걸쳐 거의 400만 개의 Motiva® 장치를 제공했으며, Motiva Flora® 조직 확장기 및 Mia Femtech™를 포함한 솔루션을 제공합니다. Establishment Labs는 코스타리카에 FDA 규정을 준수하는 두 개의 제조 시설을 운영하고 있습니다.
Establishment Labs Holdings (NASDAQ: ESTA), une entreprise mondiale de technologie médicale axée sur la santé des femmes et l'esthétique mammaire, publiera ses résultats financiers du T3 2024 le 7 novembre 2024, après la clôture du marché. L'entreprise animera une conférence téléphonique à 16h30 ET pour discuter des résultats. Depuis 2010, l'entreprise a livré près de quatre millions de dispositifs Motiva® dans plus de 85 pays et propose des solutions comprenant l'expanseur de tissu Motiva Flora® et Mia Femtech™. Establishment Labs exploite deux installations de fabrication conformes à la FDA au Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), ein globales Medizintechnikunternehmen, das sich auf die Gesundheit von Frauen und die Brustästhetik konzentriert, wird am 7. November 2024 nach Börsenschluss seine Finanzergebnisse für das 3. Quartal 2024 veröffentlichen. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Seit 2010 hat das Unternehmen fast vier Millionen Motiva® Geräte in über 85 Ländern geliefert und bietet Lösungen, die den Motiva Flora® Gewebedehnungsapparat und Mia Femtech™ umfassen. Establishment Labs betreibt zwei FDA-konforme Produktionsstätten in Costa Rica.
- Broad international presence with products available in over 85 countries
- Significant market penetration with nearly 4 million Motiva devices delivered since 2010
- Strong intellectual property portfolio with 200+ patent applications across 20 families
- Robust scientific backing with 100+ peer-reviewed studies and publications
- None.
To participate in the conference call, dial (877) 407-8037 (
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The nearly four million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024449701/en/
Investor/Media Contact:
Raj Denhoy
415 828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
When will Establishment Labs (ESTA) release Q3 2024 earnings?
How can investors join Establishment Labs (ESTA) Q3 2024 earnings call?
How many Motiva devices has Establishment Labs (ESTA) delivered since 2010?
In how many countries are Establishment Labs (ESTA) products available?
